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Abstract
Background: Human DNA topoisomerase I (top1) relaxes DNA
supercoiling during basic nuclear processes. The enzyme is the
main target of antitumor agents, such as camptothecins (CPT),
that transform top1 into a DNA-damaging agent.
Results : By directed evolution of a C-terminal portion, we
selected human top1 mutants that were 22^28-fold more CPT-
sensitive than wild-type top1 in Saccharomyces cerevisiae cells. The
evolved enzymes showed unique mutation patterns and were more
processive in plasmid relaxation assays. A top1 mutant had only
two amino acid changes in the linker domain, one of which may
change a linker/core domain contact surface. The mutant
stimulated DNA cleavage to higher levels than the wild-type
enzyme and was more sensitive to CPT in a cleavage assay.
Moreover, the mutant was more CPT-sensitive than wild-type
top1 in a repair-deficient yeast strain.
Conclusions : Mutations in the linker domain can affect
DNA binding and CPT sensitivity of human top1. Such drug-
hypersensitive topoisomerases may be useful in developing DNA
cutters with high cell lethality and in new drug discovery
programs. ß 2001 Elsevier Science Ltd. All rights reserved.
Keywords: Camptothecin; DNA shu¥ing; Drug action; Enzyme
mutant; Topoisomerase I-B
1. Introduction
Engineered DNA-binding proteins with novel character-
istics, such as site speci¢city, ligand-dependent e¡ects, spe-
ci¢c protein interactions and others, can have broad
applications in the post-genomic era. Combinatorial ap-
proaches have been used to select transcription factors
with a pre-de¢ned site selectivity, thus allowing the target-
ing and selective regulation of a few genes of interest [1].
Directed evolution by DNA shu¥ing is most powerful in
selecting mutant proteins with novel functions, new bio-
synthetic pathways [2^5] and viral genomes with increased
cell-speci¢c infectivity [6]. The basic technique explores the
sequence space of possible mutants in a combinatorial
manner, therefore avoiding a rational approach to develop
new protein functions.
Attempts to modify DNA-binding proteins other than
transcription factors have been limited. Recently, we have
shown that it is possible to alter the site selectivity of
human DNA topoisomerase I (top1) by fusion to the
DNA-binding domain of the yeast Gal4 transcription fac-
tor [7]. Top1 is an essential enzyme in multi-cellular or-
ganisms, though it is dispensable in yeast [8^10]. It relaxes
supercoiled DNA during several important nuclear pro-
cesses, such as replication and transcription, by coupling
DNA breaking and rejoining activities [8,9]. Top1 intro-
duces single-stranded breaks in a duplex, and before re-
sealing the cut, it allows the free end of the broken strand
to rotate around the intact strand resulting in relaxation of
superhelical tension [11,12]. Human top1 is constituted by
several domains (Fig. 1A), and crystal structures showed
that it clamps fully around a double helix with the non-
conserved linker domain protruding from one side of the
clamp [11,13]. The linker domain is constituted by two K-
helices and may contact DNA modulating the rotation of
the broken strand around the other [11^13].
Top1 is also the cellular target of the antitumor drug
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camptothecin (CPT) that hinders the rejoining reaction,
thus stabilizing a transient DNA^protein complex, where-
in a DNA strand is cut and covalently linked to a tyrosine
residue [9,14,15]. Trapped DNA^top1 complexes can even-
tually collide with advancing replication forks generating
irreversible double-stranded DNA cuts and cell death
[9,16]. Therefore, drug action transforms a ‘good’ enzyme
into a ‘bad’ protein that damages the DNA [14,15,17,18].
Our long-term goal is to exploit the inherent potential of
top1 to in£ict a great harm to a cellular genome to devel-
op a nuclear toxin that can e⁄ciently kill cancer cells [7].
Here, we have explored the possibility of developing a
top1 enzyme that is normally functional, yet more prone
to be transformed into a DNA-damaging agent by CPT.
Thus, we applied DNA shu¥ing methodology to increase
CPT sensitivity of human top1 expressed in yeast.
2. Results
2.1. Library preparation
Yeast cells lacking the TOP1 gene are viable and com-
pletely resistant to CPT. Consistently, the re-introduction
of a wild-type (wt) top1 restored CPT sensitivity of cells
[20,24] (see also Fig. 2). Therefore, we have used a Sac-
charomyces cerevisiae strain, JEL1-vtop1, that lacks a
functional top1 [19] to select top1 mutants. The 2-W-based
pEZ-hTop1 plasmid carries a human wt top1 cDNA that
is expressed at low levels when JEL1-vtop1 cells are grown
in glucose, due to the leakyness of the promoter [25]. That
confers a slight CPT sensitivity to cells (Fig. 2), thus al-
lowing selection for enhanced sensitivity. In this work, we
evolved a protein segment of 100 amino acids that in-
cluded the linker and C-terminal domains (Fig. 1B) by a
DNA shu¥ing technique [2^5]. Evolution cycles were re-
peated three times, and at the second and third cycles, the
selected clones of the ¢rst and second cycles, respectively,
were used as parent clones. A 525-bp fragment was am-
pli¢ed by error-prone PCR from parent clones, digested
with DNase I and shu¥ed by primer-less PCR. Then, the
full-length DNA was ampli¢ed and cloned into a gapped
Fig. 1. Human top1 domains and evolution strategy. (A) A portion of the 2-W-based pEZ-hTop1 plasmid is shown indicating the expressed GST-fused
human top1. Protein domains are marked by colors : yellow, the N-terminal domain fused to the GSH-binding domain of GST (dashed box); blue, the
DNA-binding core domain; green, the non-conserved linker domain; and red, the C-terminal domain including the active 723-tyrosine residue (asterisk).
Numbers indicate the amino acids at domain boundaries. (B) An error-prone PCR was performed by using primers sere44 and sere11 that amplify a
fragment of 525 bp, including the region from amino acids 658 to 757. PCR products were transformed into yeast cells together with a gapped vector,
prepared by digesting the pEZ-hTop1 plasmid with NheI and BstXI endonucleases that have unique restriction sites as indicated.
Fig. 2. Enhanced drug sensitivity phenotype of evolved top1s in yeast
cells. Cytotoxicity of CPT in cells expressing top1 mutants was deter-
mined with a clonogenic assay. Colony-forming cells are reported as
percentages of control cells. Symbols are: open square, no top1; open
circle, wt top1; red circle, 5-II ; red triangle, 89-II; black circle, 15-III;
black diamond, 51-III; black up-triangle, 43-III; black down-triangle,
50-III; and black square, 50-III. Bars show standard error of the mean.
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vector by homologous recombination in JEL1-vtop1 cells
(Fig. 1B). A library of about 104 clones was obtained at
each cycle, and clones were selected with a multiple-step
procedure utilizing gradually more sensitive cytotoxicity
assays (see Section 4 for details). At the ¢rst, second and
third cycles, we selected four, two and six mutants, respec-
tively (Table 1).
2.2. CPT sensitivity of selected top1 mutants
After the clone selection process, the corresponding vec-
tors were isolated and further studied. First, CPT sensitiv-
ity of JEL1-vtop1 cells expressing the selected top1s was
determined with a clonogenic assay. The four top1 clones
of the ¢rst cycle were only slightly more sensitive to CPT
than the wt enzyme (Table 1). Nevertheless, top1s from
the second and third cycles conferred a marked higher
CPT sensitivity to yeast cells than wt top1, particularly
at low drug concentrations (Fig. 2 and Table 1). CPT
potency was di¡erent depending on the expressed enzyme:
5-II, 43-III, 53-III and 50-III enzymes sensitized yeast
from 10- to 28-fold more than wt top1. Interestingly, the
rate of increased drug sensitivity was clearly diverse at the
three cycles : we detected the greatest increase (10-fold for
5-II) at the second cycle, whereas little increase was
achieved at the ¢rst cycle, and the best mutant (43-III,
obtained at the third cycle) improved only three-fold rel-
ative to 5-II (Table 1). It can also be noted that 51-III, 26-
III, and 15-III showed a drug sensitivity similar to their
parent clones (5-II and 89-II). To test whether mutations
in other regions of the vector a¡ected cytotoxicity results,
the evolved region was swapped between 5-II, 89-II, 43-III
and 50-III, on one side, and wt top1, on the other.
Swapped vectors conferred an enhanced CPT sensitivity
to cells (not shown) to the same extent of the correspond-
ing evolved clones, thus suggesting that amino acid se-
quences of the shu¥ed protein portion (Fig. 1B) were
likely responsible for the new phenotype.
2.3. Amino acid mutations of evolved top1s
The evolved regions of the 12 selected top1 cDNAs were
fully sequenced. In addition, we determined base sequen-
ces of ¢ve clones that were selected up to the last step of
selection procedures, and were identical to wt top1 in cy-
totoxicity assays (not shown). In these clones we found 28
base mutations (25 transitions and three transversions)
and no base deletions or insertions. We also sequenced
eight random, unselected clones (unable to pass the ¢rst
screen) from the third cycle, and a total of 16 base muta-
tions (10 transitions and six transversions) were found. In
addition, two base deletions and a gross re-arrangement at
the 3P side of the evolved region were observed in three
random clones, likely expressing non-functional enzymes.
These ¢ndings suggest that the selection process was suc-
cessful in selecting functional top1s, and that about one
Table 1
CPT sensitivity of yeast cells expressing the selected enzymes and amino
acid mutations of evolved top1s
Top1 CPT cytotoxicitya Amino acid mutationsc
ID50 (WM) Increase (-fold)b
wt s 10 ^
26-I 8 1.3 K679R
45-I 8.7 1.2 R663G, D677G
32-I 9.4 1.1 A661G
25-I 10 1.0 V683I
5-II 1 10 D677G, V703I
89-II 3.4 2.9 R663G, K669R, V683I, K712R,
I728T
43-III 0.35 28 R663G, K669R, D677G, V703I,
I728T, T747A
53-III 0.40 25 R663G, K669R, D677G, V703I
50-III 0.45 22 D677G, V703I, Q704L, I728T
15-III 0.9 11 D677G, V703I, K712R, I728T
26-III 1.8 5.5 V703I, I728T, K742R
51-III 3.2 3.1 R663G, D677G, V703I, I728T
aCPT cytotoxicity was measured in JEL1-vtop1 cells bearing evolved
top1s with a clonogenic test. ID50 values are drug concentrations inhib-
iting colony formation of treated cells to 50% of control cells. They
were determined from the curves shown in Fig. 2. Drug sensitivity of
clones selected at the ¢rst cycles were only slightly di¡erent from wt
top1.
bFold increase over wt top1. Since the wt value is higher than 10 WM,
ratio values are also higher than the listed ones.
cFor the selected clones of the third cycle (III), amino acid mutations in
bold were detected at higher than expected frequency, which corre-
sponded to 0.5 since the two selected clones of the second cycle (II)
were used as parents in the third cycle. The underlined mutations were
at lower than expected frequency in the same clone set.
Table 2
Frequencies of amino acid mutations in selected and random clone sets
at the third cycle
Mutation Mutation frequency observed in
clones of the third cycle
Expected frequencya
Selected (6) Random (8)
Q633H ^b 1/8 ^
L658Q ^ 1/8 ^
R663G 3/6 3/8 1/2
K669R 2/6 3/8 1/2
D677G 5/6 4/8 1/2
A678T ^ 1/8 ^
K681R ^ 1/8 ^
V683I ^ 3/8 1/2
V703I 6/6 3/8 1/2
Q704L 1/6 ^ ^
N711I ^ 1/8 ^
K712R 1/6 2/8 1/2
T718A ^ 1/8 ^
N722Y ^ 1/8 ^
P726S ^ 1/8 ^
I728T 5/6 3/8 1/2
W736G ^ 1/8 ^
K742R 1/6 ^ ^
T747A 1/6 ^ ^
aMutation frequency in clones of the second cycle used as parents for
the third cycle. The domain border is at aa 712 (see also Fig. 1).
bNull frequency.
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amino acid mutation per clone was, on average, intro-
duced in the mutagenized cDNAs.
Among the 17 clones expressing a functional enzyme,
the linker seemed to be somewhat more prone to bear
amino acid mutations than the C-terminal domain (Table
2); that may be related to the highly conserved sequence
of the latter. All the selected clones showed unique geno-
types and the mean value of amino acid mutations per
clone increased with the cycle number (Table 1). Interest-
ingly, three amino acid changes were speci¢cally associ-
ated with the selected phenotype, whereas two other mu-
tations were apparently selected against (underlined
mutations in Table 1). Even though the numbers are low
and no statistical signi¢cance can be inferred, D677G,
V703I and I728T changes, present in the two parent clones
5-II and 89-II, were found at a frequency higher than
expected in the selected clone set of the third cycle, where-
as they were close to the expected frequency among un-
selected clones (Table 2). V683I and K712R (of clone 89-
II) were apparently selected against since one was absent
and the other was present in only one clone of the selected
set, and both were present among the unselected clone set
at the expected frequency (Table 2). The sequence analyses
thus suggest a role for D677G, V703I and I728T in deter-
mining the enhanced CPT sensitivity of top1s in JEL1-
vtop1 cells, and showed that evolution of CPT-sensitive
top1s followed a pathway that included recombination
events, as well as the emergence of new mutations at
each cycle (Table 1).
2.4. Mapping of mutations on top1 structure
The three mutations associated with the selected pheno-
type were localized on the crystal structure [11,13] and
mapped to the non-conserved linker and C-terminal do-
mains (Fig. 3), distant from the enzyme active site and a
putative CPT receptor [11,13,26]. Asp 677 is part of the
turn between the two K-helices at the tip of the linker; the
Val 703 is towards the end of the second K-helix and
makes contacts with hydrophobic residues (particularly
Leu 617) of another K-helix (from residues 611 to 630)
inserted between the linker and C-terminal domains in
3-D, but that was not evolved in the present work (Fig.
3). These two amino acids are not conserved, however the
changes might in£uence protein structure: in particular,
Val703Ile may change the hydrophobic linker surface
Fig. 3. Mapping of 5-II mutations on top1 crystal structure. The evolved region from Leu 658 to Asp 757 is shown in yellow (linker domain) and blue
(C-terminal domain). The 5-II mutations, Val703Ile and Asp677Gly, are shown in magenta. In the crystal structure, Val 703 interacts with hydrophobic
residues, including Leu 617, of the K-helix (green) from Asn 611 to Cys 630. The third mutation, Ile728Thr, associated with the evolved phenotype is
also shown in magenta, and is located in the C-terminal domain. The drawing was made with RasMol (www.umass.edu/microbio/rasmol) using PDB
entry 1A36.
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that interacts with the 611^630 K-helix. The third muta-
tion associated with the new phenotype, I728T, mapped
instead of in the C-terminal domain to somewhat closer to
the active tyrosine (Fig. 3). Therefore, the three mutations
did not cluster close together in 3-D structure.
2.5. Salt e¡ects and CPT sensitivity of the best top1
mutants
To investigate the molecular mechanisms of enhanced
drug sensitivity, we have evaluated the biochemical prop-
erties of puri¢ed top1 mutants, including 5-II, 43-III, 50-
III and 53-III. Since nuclear top1 content can a¡ect CPT
sensitivity [8,9,14,20], we ¢rstly determined 5-II top1 con-
tents in yeast cells after galactose induction, however no
detectable di¡erence was noted between wt and 5-II en-
zymes by Western blots (not shown). Puri¢ed 5-II and wt
enzymes showed identical molecular weights (Fig. 4A),
and analyses of DNA relaxation showed that the mutant
had a comparable (though somewhat higher) speci¢c ac-
tivity as wt top1 (on average 7.2 and 4.9U105 U/mg, re-
spectively). The e¡ects of KCl were clearly di¡erent: for
wt top1, DNA relaxation kinetics were much retarded by
270 mM KCl, whereas those of 5-II were minimally af-
fected by high salt (Fig. 4B,C). The molecular phenotype
was also evaluated by measuring the speci¢c activities at
150 and 270 mM KCl of 5-II, as well as the best variants
of the third cycle (Fig. 5). Supercoiled plasmid DNA was
incubated with serial 1:2 dilutions of puri¢ed variants for
a ¢xed time interval, and DNA relaxation was then eval-
uated by agarose gels. The speci¢c activity of wt top1 was
more than eight-fold decreased by 270 mM KCl, whereas
the reduction of enzyme activity was of only two-fold for
5-II and 43-III, of two- to four-fold for 53-III, and of
four-fold for 50-III (Fig. 5). Thus, the selected mutants
are less a¡ected than wt top1 by KCl concentration in
the studied concentration range, and may likely have a
higher DNA-binding a⁄nity than wt enzyme. Moreover,
Fig. 4. Relaxation activity of 5-II mutant is less a¡ected by high salt concentrations. (A) Puri¢ed wt and 5-II top1s were analyzed by Western blotting
with a speci¢c monoclonal antibody [21]. Molecular weight markers are indicated on the right. (B) Salt e¡ects on relaxation kinetics of wt and 5-II
top1. Supercoiled plasmid DNA was reacted with puri¢ed enzymes (25^32 U) for the time (min) indicated above the panel. Lane C, control DNA. On
the left: S, supercoiled DNA; R, relaxed molecules. Enzymatic reactions were carried out at 150 and 270 mM KCl, top and bottom gels, respectively.
(C) Gels similar to that of panel B were quantitatively analyzed to determine kinetic curves of DNA relaxation. Circles and squares correspond to 5-II
and wt top1, respectively. Closed and open symbols correspond to 150 and 270 mM KCl, respectively.
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the ¢ndings indicate that the enzyme phenotype may vary
among the selected top1 variants in terms of sensitivity to
salt and DNA binding.
The 5-II variant was also investigated with a cleavage
assay. KCl e¡ects were determined on DNA cleavage ac-
tivity of top1s by increasing the salt concentration in the
reaction mix. In these experiments, we used amounts of wt
and 5-II top1s that gave similar levels of DNA cuts at 150
mM KCl (Fig. 6). The DNA substrate, a 32-bp oligomer,
contained a high-a⁄nity binding site for top1 [23], and
reacted with enzymes in the presence of CPT. Cleavage
levels were markedly higher for 5-II than wt top1 by in-
creasing KCl concentration (Fig. 6), showing that cleavage
activity of 5-II was more resistant to salt. These results
further supported that the mutant may have a higher
DNA-binding activity, in agreement with DNA relaxation
¢ndings.
Moreover, wt and 5-II variant top1s were compared for
CPT sensitivity with the same cleavage test at equal pro-
tein amounts at 150 mM KCl. CPT stimulated more cleav-
age with 5-II than wt top1 over the whole range of tested
drug concentrations (Fig. 7), demonstrating that the 5-II
mutant was more sensitive to CPT than wt enzyme. In
particular, the increased drug sensitivity was marked
(six- to seven-fold) at lower drug concentrations (Fig. 7).
The 5-II amino acid changes, however, did not alter the
site selectivity of DNA cleavage since patterns of cleavage
intensity were identical for the two proteins in the studied
DNA oligomer, as well as in longer fragments, such as
simian virus 40 DNA (Fig. 7 and not shown).
Fig. 5. Relaxation activity of top1 variants at diverse KCl concentrations. Supercoiled plasmid DNA (indicated by arrows) was reacted with puri¢ed en-
zymes (two-fold serial dilutions indicated above each lane) for 30 min at 37‡C. Lanes C, control DNA. Enzymatic reactions were carried out at 150
and 270 mM KCl, as indicated at the bottom of gels. Representative gels are shown. At 150 and 270 mM KCl, respectively, full-relaxation activity was
present at: 1:16/1:32 and 1:2 dilutions (at least eight-fold reduction) for wt top1; 1:2 and 1:1 dilutions (two-fold reduction) for 5-II; 1:16/1:8 and 1:4
dilutions (four-fold reduction) for 50-III; 1:8/1:16 and 1:4 dilutions (two- to four-fold reduction) for 53-III; 1:8 and 1:4 dilutions (two-fold reduction)
for 43-III.
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2.6. E¡ects of expression of 5-II top1 in a repair-de¢cient
yeast strain
The 5-II mutant was also studied in JN2-134top1-1
yeast strain that is defective for homologous recombina-
tional DNA repair, and is thus more sensitive to topo-
isomerase poisons [10,20]. In agreement with the data on
the JEL1 strain, the evolved top1 conferred enhanced CPT
sensitivity to JN2-134top1-1 cells since the drug ID5% was
almost three-fold lower for 5-II (Table 3).
We must also note that the cloning e⁄ciency of JN2-
134top1-1 cells was reduced by both proteins under our
experimental conditions, indicating a slight toxicity of hu-
man top1 for repair-de¢cient yeast cells. In contrast, the
cloning e⁄ciency of the repair-competent JEL1-vtop1
strain was minimally, if any, a¡ected by wt and 5-II en-
zymes (Table 3). After galactose activation of enzyme ex-
pression, JEL1-vtop1 cell growth was not di¡erent among
wt, 5-II, 51-III, 50-III and 43-III top1s (not shown), doc-
umenting that the evolved human proteins were not toxic
to repair-pro¢cient yeast cells even at high expression lev-
els. Interestingly, the 5-II enzyme was two-fold more ef-
Fig. 6. Cleavage activity of 5-II mutant top1. (A) Salt e¡ects on top1-promoted DNA cleavage. A DNA oligomer containing a high-a⁄nity binding site
for top1 [23] was radioactively 3P-end labeled and then reacted with wt or 5-II top1 with the indicated concentrations of CPT. The amounts of the two
enzymes were added to obtain similar cleavage levels at 150 mM KCl. Reactions were terminated by SDS addition and DNA analyzed by sequencing
gels. On the right, a bar indicates the full-length oligomer and an arrow indicates the cleaved band. Lane C, untreated DNA. At the bottom, each tri-
angle indicates 150, 170, 190, 210, 230 and 250 mM KCl, from left to right. (B) Cleavage levels at 10 WM CPT versus KCl concentration, determined
from gels similar to that of panel A. Standard errors of the mean are within 23% of indicated values. Dashed and black bars correspond to wt and
5-II top1s, respectively.
Fig. 7. CPT sensitivity of wt and 5-II top1s. A DNA oligomer contain-
ing a high-a⁄nity binding site for top1 [23] was radioactively 3P-end la-
beled, reacted with 50^70 ng of wt or 5-II top1 in the presence of di¡er-
ent CPT concentrations for 30 min at 37‡C, and then processed as in
Fig. 5. Cleavage levels were then measured by phosphorimager analyses.
Open and closed squares are 5-II and wt top1s, respectively.
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fective than wt top1 in reducing the cell cloning e⁄ciency
of repair-de¢cient JN2-134top1-1 cells (Table 3). Alto-
gether, the ¢ndings thus indicated that 5-II likely pro-
moted higher levels of genomic cleavage than wt top1, in
agreement with observations on puri¢ed proteins (Figs. 6
and 7).
3. Discussion
Our results demonstrate that directed evolution of a
eukaryotic DNA-binding protein, human top1, can be
achieved in yeast by DNA shu¥ing. Novel top1 variants
have been evolved that are more e⁄ciently transformed
into lethal toxins by CPT. Although clones of the ¢rst
cycle gave a weak phenotype, we could get a more marked
phenotype at the second (5-II) and third (43-III) cycles. At
each cycle, selected clones of the previous one were used as
parent clones, and analyses of the genotypes of all selected
clones (Table 1) clearly suggest that the combination of
recombination events and novel mutations generated the
new selected clones, in agreement with previous ap-
proaches of DNA shu¥ing [2^6].
Top1 mutants with a high toxicity to cells were known
already, and they showed a much greater tendency to
damage cellular DNA [27,28]. However, those mutants
are toxic by themselves, whereas our evolved top1s remain
fully and normally functional, and are not lethal by them-
selves in DNA-repair pro¢cient yeast cells. That re£ects
our selection process : the selection pressure during the
evolution cycles was not only for increased sensitivity to
the drug (CPT), but also for cell growth. Thus, in order to
be selectable, the plasmid-encoded top1 needed to be not
harmful to yeast cells without drug.
Many CPT-resistant top1 variants were described
[9,10,29^31] providing information on structure^function
relationships of the enzyme. To our knowledge, our work
is the ¢rst reporting on human top1 mutants that are in-
stead more sensitive to CPT. Molecular analyses of the
5-II variant, as well as of the best three variants (Table
1), show that the evolved top1s likely have a higher
apparent DNA-binding a⁄nity. The three best variants
(50-III, 53-III, and 43-III) have four or six mutations,
but each has a unique mutation pattern. All the mutations
are distant from the putative CPT receptor site
[9,11,13,15,25,26], likely indicating that they do not di-
rectly a¡ect CPT interactions with top1^DNA complexes.
Rather, overall conformational dynamics of the protein
may be altered in such a way to increase apparent DNA
binding and CPT sensitivity.
Three mutations, D677G, V703I, and I728T, were
found to be associated with selected phenotype. D677G
and V703I (the only mutations of 5-II mutant) are located
in the linker domain, which is not conserved in eukaryotic
top1s [8,9] and is even absent in some instances, such as
the vaccinia virus top1 [32]. Based on the crystal structure,
it has been proposed that the linker domain may function
as a brake of the rotation of the broken strand around the
uncut strand during the catalytic cycle [11,13]. An alter-
ation of this function may lead to a higher number of
strand rotations per catalytic cycle and may a¡ect enzyme
processivity and apparent DNA binding. We have indeed
presented ¢ndings suggesting such biochemical di¡erences
between the 5-II variant and wt top1. Moreover, the best
variants of the third cycle (43-III, 50-III, and 53-III) were
less sensitive to KCl than wt top1, indicating that a con-
sistent phenotype was selected. However, whether the al-
tered linker structures of our variants result in a dimin-
ished break^rejoining activity of top1 needs to be
established with a suicide DNA substrate.
The contribution of each mutation to the evolved top1
phenotype remains to be established. However, the DNA
shu¥ing technology often results in the selection of pro-
teins with several mutations. In our case, it is intriguing to
note that the Thr729Ala mutation (adjacent to I728T, Ta-
ble 1) was reported to confer CPT resistance [31]. A single-
mutant top1 with a Thr residue at 728 was only slightly
di¡erent, if any, from wt top1 in cytotoxicity assays (un-
published data). Since DNA shu¥ing is a powerful tool to
select combinations of mutations that a¡ect protein phe-
notypes weakly when alone and markedly when combined
[4,5,33], the I728T mutation might contribute to the
evolved phenotype only when with other mutations. Our
best variants, 50-III, 53-III and 43-III have distinct muta-
tion patterns, indicating that, in these cases, enhanced
CPT sensitivity may likely be determined cooperatively
by amino acid changes.
An increase of DNA binding and/or an altered break^
rejoining activity can likely enhance the stability of DNA^
drug^top1 complexes. Thus, CPT action is favored and
the enzyme becomes more CPT-sensitive. Consistently, a
common mechanism of drug resistance of top1 is a de-
crease in DNA binding [9,25,28]. It is also interesting to
note that the vaccinia top1, which lacks a linker domain, is
very resistant to CPT [28,32]. The in£uence of the linker
domain on CPT sensitivity has been investigated recently
Table 3
E¡ects of 5-II mutations on yeast cloning e⁄ciency and CPT sensitivity
in a rad523 straina
Enzyme Cloning e⁄ciency (%) CPT cytotoxicity in
JN2-134top1-1
JEL1-vtop1 JN2-134top1-1 ID5% (WM)b
no top1 100 100 nd
wt top1 79 33 0.31
5-II top1 90 16 0.12
aTop1 cDNAs were expressed from the 2-W-based pEZ-hTop1 plasmid,
and the assays were performed in 2% glucose. JN2-134top1-1 is rad523,
thus lacking the homologous recombinational repair pathway, and
JEL1-vtop1 is a repair-pro¢cient strain [20].
bCytotoxicity was measured with a clonogenic test. ID5% values are
CPT concentrations reducing colony formation to 5% of respective un-
treated cells. nd, much higher than the highest dose used (10 WM).
CHBIOL 123 10-9-01 Cyaan Magenta Geel Zwart
878 Chemistry & Biology 8/9 (2001) 871^881
by deleting large protein portions [34,35]. A ¢rst work on
reconstituted human top1 showed that the lack of the
whole linker domain decreased DNA binding and cleavage
levels with CPT [34]. Another report from the same group
[35] described a deletion of residues 660^688 that corre-
sponds essentially to the ¢rst quarter of the evolved region
of this work (Fig. 3). Such a deleted top1 could be puri¢ed
as monomeric and dimeric enzyme forms. Interestingly,
the monomeric form was insensitive to CPT and distrib-
utive in relaxation assays, whereas the dimeric form was
CPT-sensitive and -processive. The similarity of dimeric
form to wt top1 was discussed by the authors in terms
of some structural features of the dimer that can surrogate
a full-functional linker [35]. Our ¢ndings on evolved top1s
demonstrate that amino acid mutations in the linker do-
main can a¡ect enzyme processivity and CPT sensitivity,
and are thus in agreement with the above results. Our data
however, do not rule out the possibility that some muta-
tions of the evolved enzymes can alter other molecular
mechanisms as well.
Here, we evolved a relatively short sequence (100 aa) of
human top1, however, the procedure could be applied to
longer sequences as well, thus evolving several domains at
the same time. The design of CPT-hypersensitive top1
mutants is a step towards the development of a nuclear
DNA-damaging toxin that might be used to speci¢cally
destroy cancer cells or pathological microbes in a suicide
gene-therapy approach [7]. Moreover, drug-hypersensitive
top1s can be valuable tools to improve the sensitivity of
assays used in current screening programs to ¢nd novel
anticancer compounds.
4. Materials and methods
4.1. Materials
The 2-W-based pEZ-2ThTop1 plasmid bears a fused GST do-
main to wt human top1 under the control of a galactose-inducible
hybrid promoter [7]. JEL1-vtop1 [19] and JN2-134top1-1 [20]
yeast strains, which lack the endogenous TOP1 gene, were pro-
vided by P. Benedetti (Padova University, Padua, Italy). A mono-
clonal antibody against human top1 was provided by I. Bronstein
(York University, York, UK) [21]. CPT was purchased from
Sigma, St. Louis, MO, USA.
4.2. Library of shu¥ed top1 cDNA
The full-length human top1 was fused to the GSH-binding
domain of Schistosoma japonicum GST enzyme and cloned into
pEMBLyex4 plasmid, resulting in pEZ-hTop1 plasmid as de-
scribed already [7]. The evolved fragment was from nucleotides
2186 to 2483 (297 bp) of top1 cDNA, corresponding to the linker
and C-terminal protein domains (Fig. 1B). Two primers, sere44
and sere11, external to this region, were designed to amplify a
525-bp fragment (from 2072 to 2597 bases) that shares terminal
sequences of about 115 bp with pEZ-hTop1 DNA digested with
NheI and BstXI endonucleases (Fig. 1B). Thus, steps of evolution
cycles were the following: (A) Error-prone PCR to amplify the
525-bp fragment was performed as described [22]: reactions were
in 67 mM Tris^HCl, pH 8.8, 6.1 mM MgCl2, 1 mM each dNTP,
16.6 mM ammonium sulfate, 6.7 WM EDTA, 10 mM L-mercap-
toethanol, 10% dimethyl sulfoxide, 48 nM each primer, 30 ng of
sere11 and sere44, 5 U Taq polymerase (Perkin-Elmer) for 30
cycles of 1/1/2 min at 95/42/72‡C. (B) Random fragmentation
of PCR products [4,5] : 15 Wg of DNA was incubated in 50
mM Tris^HCl, pH 7.4, 1 mM MgCl2, with DNase I 0.3^0.4 U
in 70 Wl for 1 min at 25‡C and stopped with EDTA and SDS. (C)
After gel-puri¢cation of fragments, DNA was re-assembled [4,5]
by PCR without primers in 10 mM Tris^HCl, pH 9.0, 50 mM
KCl, 2.2 mM MgCl2, 0.2 mM each dNTP, Triton X-100 0.1%,
and 2.5 U of Taq polymerase (Promega) for 45 cycles of 0.5/0.5/
0.5 min at 94/54/72‡C. (D) The 525-bp fragment was PCR-am-
pli¢ed using sere44 and sere11 with standard PCR conditions. (E)
Cloning of 525-bp fragments into pEZ-2ThTop1 by homologous
recombination in JEL1-vtop1 yeast. Vector DNA was digested
with BstX1 and NheI, and fragments were puri¢ed with gel elec-
trophoresis. Then, yeast cells were transformed with gapped plas-
mid and shu¥ed PCR product in a 5^10U103 molar excess. Ex-
ponentially-growing cells were washed and resuspended in 0.1 M
Li-acetate, 10 mM Tris^HCl, pH 7.5, 1 mM EDTA. 2 Wg of
DNA with 100 Wg of salmon sperm DNA were added to cells
in 40% PEG 4000, 0.1 M Li-acetate, 10 mM Tris^HCl, pH 7.5,
1 mM EDTA. After 1 h of incubation at 30‡C, cells were shocked
at 42‡C for 1 min, centrifuged, washed, and plated to have 100^
180 colonies/plate. (F) Selection of clones for increased cell sen-
sitivity to CPT by replica plates in synthetic complete (SC)-uracil
medium.
4.3. Selection and sequencing of CPT-hypersensitive clones
Libraries of 0.8^1U104 clones were prepared, and clones were
initially selected by replica plating for enhanced sensitivity to 10
(¢rst and second cycles) and 3 WM (third cycle) of CPT. This step
selected 65^130 clones. A second screen was then performed: 1:5
serial dilutions of cells of selected clones were spotted onto plates
containing SC-uracil medium without or with 3 or 10 WM CPT.
With the second screen we usually selected 15^17 clones. Then, a
third screen was performed with an in-liquid assay (see below),
which reduced the selected clones to 6^8. The plasmids were
recovered from ¢nal clones, and re-transformed into fresh
JEL1-vtop1 cells. Then, new colonies were recovered and tested
with the in-liquid assay. At each step, clones showing a higher
sensitivity than wt top1 were selected and proceeded to the next
one. CPT lactone form was always used throughout this work.
Cell killing assays were: (A) In-liquid cytotoxicity test. Expo-
nentially-growing cells were diluted to 0.5 OD600nm in SC-uracil
medium and incubated with di¡erent CPT concentrations for 18
h at 30‡C. Cell growth inhibition was then tested by measuring
the OD600nm of cell cultures. (B) Clonogenic test. CPT sensitivity
of selected top1s was determined in vivo by a colony-forming
inhibition assay. Exponentially-growing cells were treated with
di¡erent CPT concentrations for 18 h at 30‡C, then appropriate
dilutions of cultures were plated in duplicate in SC-uracil medium
and colonies were allowed to grow for 3^4 days. Cell survival was
determined as ratios of the numbers of colonies formed by
treated and control cells.
Sequencing of evolved regions was performed on an automated
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£uorescent ABI PRISM 377 DNA sequencer using the T7 Se-
quencing Kit (Pharmacia).
4.4. Biochemical assays
Evolved and wt top1s were puri¢ed from yeast nuclear extracts
with ammonium sulfate precipitation, phosphocellulose chroma-
tography and a⁄nity chromatography as described [7]. DNA
relaxation and cleavage assays, Western analyses, and 32P-3P-
end labeling of DNA oligomers were performed as extensively
described already [7]. Brie£y, negatively-supercoiled pBR322 plas-
mid DNA (250 ng) was incubated with 25^32 U of enzyme in 20
mM Tris^HCl, pH 7.8, 10 mM MgCl2, 0.2 mM EDTA, 0.1 mM
EGTA, 0.1 mM dithiothreitol, 24.5 mg/ml bovine serum albumin,
4.5% glycerol, and 150 or 270 mM KCl for the indicated time at
37‡C. After gel electrophoresis, stained gels were analyzed with
Bio-Rad Gel Doc 1000, and relaxed DNA determined with Bio-
Rad Molecular Analyst software. A 32-bp DNA oligomer con-
taining a high-a⁄nity binding site for top1 [23] was used as the
substrate in cleavage assays. DNA cleavage was analyzed by 17%
polyacrylamide sequencing gels, and levels were determined by
PhosphorImager (Molecular Dynamics) analyses as reported al-
ready [7].
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